What is AbCellera Biologics Inc.'s R&D?

AbCellera Biologics Inc. (ABCL) reported R&D of $46.66M in Q1 2026.

How has AbCellera Biologics Inc.'s R&D changed year-over-year?

AbCellera Biologics Inc.'s R&D increased by 9.8% year-over-year, from $42.5M to $46.66M.

What is the long-term trend for AbCellera Biologics Inc.'s R&D?

Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s R&D has grown at a 31.7% compound annual growth rate (CAGR), from $62.06M to $186.83M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

AbCellera Biologics Inc. ABCL R&D

R&D at other companies

Twist Bioscience CorporationTWST

$19.7M-17.7%

Recursion Pharmaceuticals, Inc.RXRX

$87.9M-32.2%

AnaptysBio, Inc.ANAB

$33.99M-17.5%

PrecigenPGEN

$5.64M-46.2%

ZymeworksZYME

$34.46M-3.6%

ADMA BiologicsADMA

$2.6M+214%

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.72B+59.2%

Enterprise value$1.76B+100.0%

P/S21.7×-25.0×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s R&D?: AbCellera Biologics Inc. (ABCL) reported R&D of $46.66M in Q1 2026.
How has AbCellera Biologics Inc.'s R&D changed year-over-year?: AbCellera Biologics Inc.'s R&D increased by 9.8% year-over-year, from $42.5M to $46.66M.
What is the long-term trend for AbCellera Biologics Inc.'s R&D?: Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s R&D has grown at a 31.7% compound annual growth rate (CAGR), from $62.06M to $186.83M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.